NewAmsterdam Pharma Reports Q3 Loss of $0.14 Per Share

NewAmsterdam Pharma Co N.V. reported third-quarter 2026 revenue of $19.2 million, compared with $0.3 million a year earlier, including an $18.3 million regulatory milestone from Menarini. Net loss narrowed to $17.4 million from $72 million, while loss per share was $0.14 versus $0.61.Financial High…